Clinical Trial Detail

NCT ID NCT03228667
Title QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Altor Bioscience Corporation
Indications

lung non-small cell carcinoma

Therapies

ALT-803 + Nivolumab

ALT-803 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.